Stock Market Reviews

CRIS (Curis, Inc.) News

Get the latest news, insights, and market updates on CRIS (Curis, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Curis to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2025
  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its second quarter 2025 financial and operating results on Tuesday, August 5, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET.
  Jul 29, 2025 - $CRIS
• Wall Street Set to Open Lower Wednesday as Jobs Data Misses Forecasts
  US stocks look set to open lower in Wednesday's trading session as key employment data missed analys
  Jul 2, 2025 - $CRIS
• Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement
  Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into a definitive agreement with a combination of existing and new investors for the purchase of 1,538,460 shares ("Shares") of its common stock in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Curis also agreed to issue to the investors
  Jul 2, 2025 - $CRIS
• Curis Inc (CRIS) Q1 2025 Earnings Call Highlights: Financial Improvements and Strategic Developments
  Curis Inc (CRIS) reports a reduced net loss and successful financing, while advancing promising clinical studies and welcoming a new Chief Medical Officer.
  May 7, 2025 - $CRIS
• Curis: Q1 Earnings Snapshot
  LEXINGTON, Mass. AP) — Curis Inc. CRIS) on Tuesday reported a loss of $10.6 million in its first quarter.
  May 6, 2025 - $CRIS
• Curis (CRIS) Reports Q1 Loss, Tops Revenue Estimates
  Curis (CRIS) delivered earnings and revenue surprises of -9.65% and 11.74%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
  May 6, 2025 - $CRIS